http://www.reuters.com/article/pressRelease/idUS154656+08-Sep-2009+BW20090908 Teva will present data on the effect of COPAXONE® on the Multiple Sclerosis Severity Score (MSSS) from the longest ongoing prospective study of an immunomodulatory therapy in RRMS. In addition, Teva and Active Biotech (NASDAQ OMX NORDIC: ACTI) will present data on laquinimod, its investigational oral, once-daily, immunomodulating compound being developed for the treatment of RRMS. New data on ATL/TV1102, a second generation antisense inhibitor of CD49d, a subunit of VLA-4, for the treatment of RRMS patients, will be presented as well.
ANP Price at posting:
5.3¢ Sentiment: None Disclosure: Held
